All In Biotech

Free tool

FAERS Monitor: Norpace

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 017447 or its brand name (Norpace, Disopyramide Phosphate). Reports on generic versions are filed under their own applications.

Reports

853

Serious

470

55% of reports

Hospitalization

217

Death reported

40

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective140
  • off label use59
  • atrial fibrillation48
  • dyspnoea44
  • malaise43
  • fatigue42
  • palpitations32
  • dizziness31
  • asthenia27
  • feeling abnormal27
  • drug interaction23
  • product use issue23
  • constipation22
  • drug ineffective for unapproved indication22
  • loss of consciousness22

Reports by year received

View as table
YearReports
200421
200536
200613
200721
200813
200913
201042
201151
201253
201326
201471
2015144
201631
201746
201818
201927
202044
202135
202249
202321
202419
202540
202619

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,306 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
atrial fibrillationSignal4812.29.2482
drug ineffective for unapproved indicationSignal229.96.5167
palpitationsSignal326.74.8152
loss of consciousnessSignal224.22.851
drug interactionSignal233.62.440
product use issueSignal233.02.029
feeling abnormalSignal272.81.929
drug ineffectiveSignal1402.62.3148
constipationSignal222.51.618
malaiseSignal432.41.835
dyspnoea441.91.419
asthenia271.81.28
off label use591.71.316
dizziness311.51.15
fatigue421.31.03

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.